Page last updated: 2024-10-31

neostigmine and Parkinsonian Disorders

neostigmine has been researched along with Parkinsonian Disorders in 1 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
MALONE, MH1
ARZT, FC1
BRAGAN, RA1
DECATO, L1

Other Studies

1 other study available for neostigmine and Parkinsonian Disorders

ArticleYear
RESERPINE-NICOTINE INDUCED PARKINSONISM IN MICE.
    Archives internationales de pharmacodynamie et de therapie, 1965, Volume: 154

    Topics: Anticonvulsants; Atropine; Lactose; Mice; Muscle Relaxants, Central; Neostigmine; Nicotine; Parkinso

1965